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uring the past 5 to 7 years, the SGLT-2 inhibitors (SGLT2i) have been shown to improve
cardiovascular outcomes in patients with and
without diabetes,1,2 forestall kidney disease progression in patients with and without diabetes,3 and improve
mortality in patients with heart failure.4 Balancing the
long-term benefits of a suite of drugs including reninangiotensin-aldosterone system inhibitors (RAASi),
diuretics, and now SGLT2i against potential short-term
changes in renal hemodynamics and kidney function
can be vexing for even the most astute clinician. It is
therefore critical to understand predictable changes in
kidney function, as assessed by serum creatinine and
estimated glomerular filtration rate (eGFR).

Articles, see p 438 and p 450
The long-term benefits of RAASi on kidney function
are felt to be secondary to their ability to lower both systemic and intraglomerular pressure.5 The inhibition of the
renin-angiotensin-aldosterone axis induces vasodilation
of the efferent arteriole that leads to a reduction in intraglomerular pressure and potentially single nephron GFR.
Numerous studies across diverse kidney diseases demonstrated a mean decrease or “dip” in eGFR in patients
randomized to RAASi in the first 1 to 3 months followed
by a less steep fall in eGFR compared with placebo, preserving kidney function with decreased end-stage kidney
disease and doubling of serum creatinine.6,7 This led to
the advice to clinicians to tolerate up to a 30% increase
in the serum creatinine on initiation of a RAASi. In addi-

tion, several studies in varied settings (heart failure, kidney disease) have demonstrated that patients who have
an acute drop or “dip” in GFR have a slower decline in
kidney function over time compared with those who do
not have a “dip.”8–10 Initial studies with SGLT2i noted a
similar early decrease in eGFR, stimulating interest in the
potential mechanism for this decrease and its potential
prognostic significance.
In this issue of Circulation, Adamson et al11 report on
initial eGFR changes on initiation of dapagliflozin in the
DAPA-HF trial (DAPA-Heart Failure). The overall results
of the trial showed a reduction in mortality and heart failure events in participants with heart failure and reduced
ejection fraction.4 The results of this trial population
level analysis demonstrated an average decrease of
4.2 mL/min/1.73 m2 (95% CI, –4.64 to –3.85) of eGFR
within the first 14 days of treatment with dapagliflozin
followed by a less steep decline in eGFR compared with
placebo. The authors also noted that 38.2% of the 2309
participants randomized to dapagliflozin had a >10%
decline in eGFR 14 days after initiation of therapy. Only
3.4% had a decline in eGFR of >30%. The authors
noted that older age, lower eGFR, type 2 diabetes, and
higher ejection fraction were associated with a >10%
decline in eGFR. It is important that patients experiencing a >10% early decrease in eGFR on dapagliflozin
had significantly better clinical outcomes, including cardiovascular outcomes as well as a slower chronic rate of
decline in eGFR, than among participants assigned to
dapagliflozin with an eGFR decline of ≤10%. Conversely,
those experiencing the same initial decline in eGFR during treatment with placebo had worse outcomes than
those with an eGFR decline of ≤10% on placebo.
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The analysis and characterization of initial eGFR
“dip” in patients with heart failure treated with dapagliflozin reported by Adamson et al11 is consistent with
data reported from the analysis of other large kidney
and heart trials involving SGLT2i. The results of an analysis of the EMPA-REG OUTCOME trial reported the
median reduction in eGFR at 4 weeks was 2.69 mL/
min/1.73 m2 and that a >10% eGFR decline occurred
in 28.3% of empagliflozin-treated participants.12 These
results also noted that participants with type 2 diabetes
and more advanced kidney disease were more likely
to experience a >10% decline in eGFR on initiation of
SGLT2i. A post hoc analysis of the CREDENCE kidney
trial data showed 45% of canagliflozin-treated participants experienced an acute eGFR drop of >10% and
a neutral effect on the subsequent decline in eGFR
compared with participants who did not “dip” on canagliflozin. A >30% drop in eGFR was noted in only 4%
of participants in the canagliflozin group.13
Adamson et al11 also noted that more advanced kidney disease was an independent predictor for the initial
decline in eGFR. This may reflect that this independent
predictor has some mechanistic probability. It may also be
confounded by simple mathematics. For example, participants with an eGFR in the 60s would need to drop their
eGFR by 6 mL/min/1.73 m2 to reach the 10% decline
threshold, whereas those with eGFRs in the 30s would
need to decline by only 3 mL/min/1.73 m2.
Multiple mechanisms are postulated to drive the
physiologic and metabolic changes, including the initial
decline in eGFR seen with initiation of SGLT2i. Changes
in tubuloglomerular feedback have been postulated to
explain both the short-term (“dip”) and long-term (GFR
preservation) effects. This hypothesis holds that SGLT-2
inhibition reduces sodium and glucose reabsorption in
the proximal tubule, which thereby increases sodium
delivery to the distal nephron (macular densa) leading
to constriction of the afferent renal arteriole and resulting in a reduction of GFR and intraglomerular pressure.
However, there are reasons to question whether this
is the primary explanation because tubuloglomerular
feedback resets during the long term and the benefits
also are apparent in people without diabetes where
the SGLT2i effect on proximal sodium reabsorption
should be less pronounced. In this issue of Circulation,
this mechanistic hypothesis is explored meticulously by
Lytvyn and colleagues14 in patients with type 1 diabetes
on angoitensin converting enzyme inhibitor and SGLT2i
alone and in combination.
Lytvyn et al14 recruited a sample of 30 volunteers
with type 1 diabetes and relatively intact kidney function
(mean eGFR of 121 mL/min/1.73 m2) and performed
detailed physiologic studies under euglycemic clamp
conditions including direct measurement of GFR (inulin
clearance), estimated renal plasma flow (para-aminohippurate), urine studies to assess renal sodium handling,
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and a suite of noninvasive assessments of cardiovascular
function. It included a run-in period in which participants
were established on background ramipril therapy, and a
placebo-controlled cross-over phase in which each participant received either placebo or empagliflozin for a
period of 4 weeks. At baseline, these participants had
normal blood pressure (mean systolic blood pressure,
112 mm Hg) and measured GFR (mGFR) of 116 mL/
min. There was a slight drop in systolic blood pressure
and in renal vascular resistance with initiation of ramipril
but no change in mGFR. The change in renal vascular
resistance is in line with the known physiology of both
afferent and efferent arteriolar dilation. The absence of a
detectable change in mGFR may stem from the fact that
systolic blood pressure declined minimally, and thus the
reduction in intraglomerular pressures, and thereby glomerular filtration, is less than expected in a hypertensive
population, or it may reflect the relatively small sample
size. Subsequently, the addition of empagliflozin on background ramipril therapy revealed a drop in mGFR of 5
mL/min as well as large decreases in absolute proximal
fluid and sodium resorption rates. The addition of empagliflozin reduced blood pressure and total peripheral
resistance further but otherwise did not generate any
significant changes in hemodynamic parameters. Among
metabolic changes noted, 8-isoprostane and cGMP
decreased significantly with empagliflozin.
The mechanistic study by Lytvyn et al14 illustrates a
modest drop in mGFR with the addition of an SGLT2i to
background RAASi therapy. The mGFR data are somewhat limited because of the lack of expected response
to RAASi therapy alone. This may be a result of acknowledged sample size/power issues with the study or physiologic differences in the subject pool (type 1 diabetes,
young age, relatively normal baseline blood pressure
and mGFR). More interesting is the reduction in urinary
8-isoprostane levels, which is a known marker of renal
oxidative stress. The reduction in oxidative stress suggested by the reduction in urinary 8-isoprostane levels is
intriguing and may give a clue to mechanisms other than
changes in tubuloglomerular feedback.
The mechanistic and clinical trial data are consistent.
Initiation of an SGLT2i in a population of patients with
heart failure results in a “dip” in eGFR of >10% in fewer
than half of the patients within the first month of therapy,
with an average for the population a modest 3 to 5 mL/
min/1.73 m2 reduction in eGFR. This “dip,” if it occurs
at all, is generally small and may actually be associated
with long-term benefit, certainly not harm. Thus, the fear
of a large acute decline in kidney function should not
be a prominent factor in the decision to start (or hold)
a SGLT2i. Given the increasingly documented clinical benefits of SGLT2i, clinicians should anticipate this
early decline and stay the course by continuing therapy.
Because RAASi or over diuresis can also cause a “dip”
eGFR, when starting SGLT2i, it is prudent to maintain
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stable doses of diuretics and RAASi to avoid inadvertently
attributing a larger “dip” of eGFR to the SGLT2i. Given
that larger declines (>30% worsening in eGFR or >0.5
mg/dL increase in serum creatinine) are uncommon
with SGLT2i initiation, a large creatinine increase should
prompt evaluation for other factors contributing to the
change in creatinine such as volume depletion or nephrotoxin exposure. Most patients started on SGLT2i will
experience either no change or minor changes in kidney
function, and thus staying the course on SGLT2i is the
right course of action.
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